Search

Displaying results 9791 - 9800 of 10000 in total
  1. Drug

    IDM-1

    go.drugbank.com/drugs/DB05292
    Experimental

    It is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific anti-HER-2/neu antibody developed by Medarex Inc. … IDM-1 is IDM’s most advanced antibody-based Cell drug for the treatment of cancer.

  2. Drug

    SR-9009

    go.drugbank.com/drugs/DB14013
    Experimental

    SR-9009 is a REV-ERB agonist. … SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues

  3. Drug

    MVC-COV1901

    go.drugbank.com/drugs/DB15854
    Investigational

    As of September 2020, the vaccine candidate is in Phase 1 clinical trials to assess its safety and immunogenicity (NCT04487210). … MVC-COV1901 is a vaccine candidate developed and commercialized by Medigen Vaccine Biologics Corporation. The vaccine candidate contains a perfusion form of the SARS-Cov2 recombinant spike protein.

  4. Drug

    BBIBP-CorV

    go.drugbank.com/drugs/DB15807
    Investigational

    As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials. … Investigation shows this vaccine induces neutralizing antibodies in several mammalian species while also showing protective efficacy with SARS-CoV-2 challenge in rhesus macaques[A219763].

  5. Drug

    Lumicitabine

    go.drugbank.com/drugs/DB14808
    Investigational

    Lumicitabine is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and … Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations).

  6. Drug

    AMP-201

    go.drugbank.com/drugs/DB18663
    Experimental

    AMP-201 comprises an adeno-associated virus type 8 vector (AAV8) encoding the collagen Q gene (COLQ). It is under investigation for the treatment of collagen Q congenital myasthenia.

  7. Drug

    Prostaglandin G2

    go.drugbank.com/drugs/DB03866
    Experimental

    A cyclic endoperoxide intermediate produced by the action of CYCLOOXYGENASE on ARACHIDONIC ACID. It is further converted by a series of specific enzymes to the series 2 prostaglandins. [PubChem]

  8. Drug

    Aklavine

    go.drugbank.com/drugs/DB19070
    Experimental

    Aklavine is under investigation in clinical trial NCT03026842 (Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With T(8;21)).

  9. Drug

    Fenebrutinib

    go.drugbank.com/drugs/DB14785
    Investigational

    Fenebrutinib is under investigation in clinical trial NCT03174041 (A Drug-Drug Interaction Study Between GDC-0853 and Midazolam, Itraconazole, Rosuvastatin, and Simvastatin).

  10. Drug

    Sevuparin

    go.drugbank.com/drugs/DB15007
    Investigational

    Sevuparin is under investigation in clinical trial NCT03853421 (Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin).